TransMedics Group, Inc.TMDXEarnings & Financial Report
Nasdaq
TMDX Q3 2025 Key Financial Metrics
Revenue
$143.8M
Gross Profit
$84.6M
Operating Profit
$23.3M
Net Profit
$24.3M
Gross Margin
58.8%
Operating Margin
16.2%
Net Margin
16.9%
YoY Growth
32.2%
EPS
$0.66
Financial Flow
TransMedics Group, Inc. Q3 2025 Financial Summary
TransMedics Group, Inc. reported revenue of $143.8M for Q3 2025, with a net profit of $24.3M (16.9% margin). Cost of goods sold was $59.2M, operating expenses totaled $61.3M.
Key Financial Metrics
| Total Revenue | $143.8M |
|---|---|
| Net Profit | $24.3M |
| Gross Margin | 58.8% |
| Operating Margin | 16.2% |
| Report Period | Q3 2025 |
TransMedics Group, Inc. Annual Revenue by Year
TransMedics Group, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $441.5M).
| Year | Annual Revenue |
|---|---|
| 2024 | $441.5M |
| 2023 | $241.6M |
| 2022 | $92.1M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $81.2M | $96.8M | $114.3M | $108.8M | $121.6M | $143.5M | $157.4M | $143.8M |
| YoY Growth | 158.7% | 133.1% | 117.9% | 63.7% | 49.8% | 48.2% | 37.7% | 32.2% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $706.0M | $723.8M | $758.6M | $785.6M | $804.1M | $837.5M | $890.5M | $946.0M |
| Liabilities | $568.8M | $564.4M | $568.7M | $575.7M | $575.5M | $571.2M | $572.4M | $590.8M |
| Equity | $137.2M | $159.5M | $189.9M | $209.9M | $228.6M | $266.3M | $318.1M | $355.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $8.3M | $-3.4M | $25.7M | $6.9M | $19.7M | $-2.9M | $91.6M | $69.6M |